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Introduction
It was reported that mid-wall striate late gadolinium
enhancement at interventricular septum (MWS-LGE)
definite by CMR was strong predictor of prognosis
including sudden death with dilated cardiomyopathy
(DCM). On the other hand, randomized trial have
shown that beta-brokers lead symptomatic improve-
ment, reduced hospitalization and enhanced survival in
many patients with heart failure.
Purpose
The object of this study was to evaluate the impact of
mid-wall striate of LGE(MWS- L G E )a ti n t e r v e n t r i c u l a r
septum to beta-broker (Carvedilol) titrating to the target
dose and improvement of cardiac function with DCM.
Methods
Fifty-five patients with DCM examined by LGE-CMR
were enrolled. They were treated with Carvedilol at
higher dose as possible.
They were divided into two groups according to
MWS-LGE positive or not.
The maximum dose of Carvedilol with each group at
chronic stable condition(after 21.6 +/- 21.4 months later
from initiation of Carvedilol) were compared. The improve-
ment of UCG parameter of each group by Carvedilol
therapy was examined.
Results
1) The UCG parameters of all 55 DCM patients
recorded just before initiation of Carvedilol were LVDd;
65.2±7.5mm,LVDs; 56.3±8.5mm,EF;28.2.±8.1% and mean
final dose of Carvedilol with all 55 DCM patients was
11.5±5.5mg.
2) MWS-LGE was found in twenty patients of DCM
(38.1%) with LGE-CMR.
3) There were no significant difference between two
groups in LVDd, LVDs and EF(P>0.79,P>0.92,P>0.76,
respectively)at first echocardiograph.
4) The final dose of carvedilol with MWS-LGE -positive
group was lower than with MWS-LGE -negative group
(9.2+/-5.4 mg VS 13.0 +/-5.1mg, respectively).
5) The UCG parameter showed improvement at chronic
stable phase compared to those had recorded at just before
initiation of Carvedilol in the both groups, but especially in
the MWS-LGE negative group showed a greater improve-
ment than those of MWS-LGE positive group (Table 1).
Conclusions
The relationship between the beneficial effect of Carve-
dilol with DCM and MWS-LGE defined by LGE-MRI
was examined. The DCM patients with MWS-LGE
negative showed higher maximum dose of Carvedilol
and greater improvement of UCG parameters compared
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Table 1 The UCG parameters at chronic stable phase
MWS-LGE LVDd(mm) LVDs(mm) EF(%)
Negative 54.4+/-7.7 39.8+/-9.9 52.3+/-14.2
Positive 63.1+/-10.9 52.4+/-14.8 36.2+/-18.1
P-value <0.02 <0.02 <0.01
Teraoka et al. Journal of Cardiovascular Magnetic Resonance 2011, 13(Suppl 1):P274
http://jcmr-online.com/content/13/S1/P274
© 2011 Teraoka et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.to those of patients with MWS-LGE positive. The
MWS-LGE has a potential to have a strong worse
impact to titrating and beneficial effect of Carvedilol
with DCM.
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